About the Company
VeriStrat is a test developed to evaluate patient prognosis and, additionally, predict benefit from cancer treatment by EGFR inhibitors. It is a serum/plasma proteomic test developed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. VeriStrat was developed by Biodesix, Inc., a molecular diagnostics company based in Boulder, Colorado, US. The VeriStrat algorithm has been interrogated retrospectively and prospectively in samples from randomized trials, such as the PROSE study, confirming the prognostic information associated with the molecular signature. In addition, the test appeared to be predictive of erlotinib impact on survival, as only "VeriStrat Good patients" benefited from such a treatment. Additional studies have confirmed its clinical relevance.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BDSX News
Biodesix, Inc. (BDSX)
LOUISVILLE, Colo., April 09, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American ...
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at ...
Gold Surges Over 1%; Biodesix Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow traded up 1.01% to 38,987.23 while the NASDAQ rose 1.50% to 16,289.37. The S ...
Biodesix, Inc. (BDSX) Interactive Stock Chart - Yahoo Finance
LOUISVILLE, Colo., April 09, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American ...
Biodesix Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Biodesix (NASDAQ: BDSX)
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung ...
Biodesix prices its 17.4M shares offering at $1.15 apiece
Additionally, the company entered into securities purchase agreements for a concurrent private placement of 760.9K shares of its series A non-voting convertible preferred stock for $46 per share ...
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new ...
Loading the latest forecasts...